2ND ANNUAL

MARCH 7-8, 2023

DEC⊙DE:

AI for Pharmaceutical Executives

HILTON SAN DIEGO BAYFRONT | SAN DIEGO, CA

Innovations, Implementations, and Strategies to Advance Patient-Centricity and Business Outcomes

2023 FEATURED SPEAKERS

Emma Huang
Director of Data Sciences External Innovation at the California Innovation Center, Johnson & Johnson

Unmesh Lal
Director, Healthcare & Life Sciences, Frost & Sullivan, Inc.

Petrina Kamya, PhD
Head of AI Platforms, Department of Business Development, Insilico Medicine

Boris Hayete, PhD
Senior Vice President & Head, Computational Sciences, Empress Therapeutics

Maliheh Poorfarhani
Information and Digital Solution Procurement Business Partner Lead, Roche Diagnostics

PAST SPONSORS

accenture

OWKIN

Pangaea

From the Organizers of Renowned Industry Events Spanning Tech & Life Science

aiworld
Conference & Expo

Bio·IT World
CONFERENCE & EXPO

DecodeAIPharma.com | #DECODEAIPharma

Cambridge **Healthtech** Institute

TUESDAY, MARCH 7

7:00 am Registration and Morning Coffee

IT'S ALL ABOUT THE PEOPLE: SUCCESS FACTORS FOR BUILDING THE RIGHT TEAM AND ROLLING OUT A SUCCESSFUL CHANGE MANAGEMENT STRATEGY

8:00 Chairperson's Remarks
Stefan N. Lukianov, PhD, CEO, Technology, Salve Therapeutics

8:10 Building a Fit-for-Purpose Data Sciences Team Begins and Ends with Purpose
Emma Huang, PhD, Director, Data Sciences External Innovation, California Innovation Center, Johnson & Johnson
Data science has become a critical capability for the pharmaceutical industry, but building the right team faces many challenges. I will discuss considerations around the size, composition, and fit within organizational structure of data sciences teams, and how they are affected by the purpose of the team. Deliberate design choices based on this purpose will enable fit-for-purpose recruitment and a clear sense of the team's contribution to the organization's mission.

8:40 Tackling Organizational Change Management for AI: Keys for Building a Successful Plan
Petrina Kamya, PhD, Head of AI Platforms, Department of Business Development, Insilico Medicine
Successful digital strategy adoption requires buy-in from stakeholders and those who will be implementing the strategy. This is where organizational change management plays a critical role. From IT infrastructure, legal, procurement and the end user, all departments need to be aligned, flexible and willing to put in the time in order to realize the benefits that this type of technology can have.

9:10 Sponsored Presentation (*Opportunity Available*)

9:40 Networking Coffee Break

AI IN PRACTICE: BUILDING A SUSTAINABLE AI STRATEGY

10:25 Talk Title to be Announced
Annastasiah M. Mhaka, PhD, Founder, Mawambo; Co-Founder & Former President, Alliance for AI in Healthcare (AAIH)

10:55 Knowledge Driven Sustainable Collaborations between Pharmaceutical and Healthcare Industries
Vibhor Gupta, PhD, Founder, Pangaea Data

11:25 Sponsored Presentation (*Opportunity Available*)

11:55 Session Break

12:00 pm Luncheon Presentation (*Sponsorship Opportunity Available*)

12:30 Networking Refreshment Break

AI ADOPTION AND IMPLEMENTATION TO EASE PATIENT BURDEN

1:00 What's Hard, What's Easy, and What's Cutting-Edge in AI/ML Toolbox for Drug Discovery? One Company's Perspective
Boris Hayete, PhD, Senior Vice President & Head, Computational Sciences, Empress Therapeutics
Small-molecule drugs represent great value for patients and society. The costs of failure are significant, as drug candidates that look promising in preclinical testing too often fail when tested in humans. Several companies, including Empress, seek to disrupt this paradigm by putting the last experiment first, using AI/ML to better predict and discover small molecule drug candidates likely to be safe and efficacious in humans.

1:30 Using Artificial Intelligence to Act in Real-Time for Patients: A Case Study
Shannon L. Smith, Associate Director, aTTP & Rare Blood Disorders, Sanofi
Rare and ultra-rare diseases pose unique challenges and face various barriers for both patients and healthcare providers. A combination of complex diagnosis, overworked HCPs, and a lack of awareness of approved therapies often leads to delayed diagnosis and treatment for rare disease patients. The power of AI offers insights and allows for engagement by reaching HCPs at the most optimal time to provide education and drive better patient outcomes.

2:00 Building an AI/ML BioCAD Platform for Viral Bioengineering to Ease Patient Burden
Stefan N. Lukianov, PhD, CEO, Technology, Salve Therapeutics
Salve Therapeutics is developing a bioengineering software platform called VirCAD (Virus Computer-Aided Design). This platform will allow biopharma researchers to safely, inexpensively, and rapidly mine the human virome for new viral biologics for complex diseases. Sophisticated viral therapies could treat, and possibly cure, these diseases and significantly ease patient burden and improve quality of life.

2:30 Networking Refreshment Break

EMERGING AI TECHNOLOGIES IN PHARMA

3:00 Democratizing Machine Learning and Active Learning at Novartis
Rishi R. Gupta, PhD, Associate Director, Data Science, Novartis Institute for Biomedical Research
Kian Tan, PhD, Director, Novartis Institutes for BioMedical Research (NIBR)
With the exponential growth in data and the rise of statistical methods for analyzing and optimizing within drug discovery, we have been investigating how to get these approaches infused into the Design-Make-Test-Analyze (DMTA) cycle. In this talk we will discuss tools that we have developed that allow scientists to access active learning workflows to augment compound design; in effect, our effort to democratize machine learning to the medicinal chemistry community.

3:30 **Sponsored Presentation** *(Opportunity Available)*

4:00 **PANEL DISCUSSION: Achieving Desired Patient Outcomes for More Personalized Care with Emerging AI Technologies**
Moderator: James Cooper, Professor, Director, International Legal Studies, California Western School of Law

This lively panel discussion will engage with leading pharmaceutical executives who are helping to drive the adoption and use of AI within their organizations. The panel will provide insights into their use of and experiences with some of the latest and emerging AI technologies and how these are transforming the way in which their organizations operate.

Panelists:

Emma Huang, PhD, Director, Data Sciences External Innovation, California Innovation Center, Johnson & Johnson

Petrina Kamya, PhD, Head of AI Platforms, Department of Business Development, Insilico Medicine

Maliheh Poorfarhani, Information and Digital Solution Procurement Business Partner Lead, Roche Diagnostics

Annastasiah M. Mhaka, PhD, Founder, Mawambo; Co-Founder & Former President, Alliance for AI in Healthcare (AAIH)

5:00 **Closing Remarks**

5:05 **Welcome Networking Reception**

6:00 **Close of Day**

WEDNESDAY, MARCH 8

7:30 am **Registration Open**

RISK, MITIGATION, AND BUILDING TRUST WITH AI

7:55 **Chairperson's Remarks**

8:00 **AI Regulatory Sandbox: A Perfect Fit with Pharma**
Jos van der Wijst, Owner & Tech Lawyer, Intellectual Property, BG.legal

The introduction of the EU AI Act brings with it the requirement for an AI regulatory sandbox, which provides a great opportunity for the pharmaceutical industry. AI developers and regulators need to develop a legal framework that works for all of them. When they succeed, this instrument can contribute to the use of explainable/trustworthy AI in Pharma.

8:30 **Overcoming Data Bias with AI and Advanced Data Science**

Brandon Allgood, PhD, Chief AI Officer, Valo Health

Bias in medicine is not a new phenomenon. With the introduction of AI we have the opportunity to ignore it and make it infinitely worse or to acknowledge it and use the introduction of AI and data science to help correct it. I will discuss the history of bias, what imprint that leaves on the data we have, and how we can build teams and models to help correct this.

9:00 **Sponsored Presentation** *(Opportunity Available)*

9:30 **Networking Coffee Break**

TRENDS AND BENCHMARKS: AI ADOPTION ACROSS THE PHARMACEUTICAL INDUSTRY

10:15 **Artificial Intelligence Accelerates Drug Discovery – Status & Opportunities**
Unmesh Shankar Lal, Director, Healthcare & Life Sciences, Frost & Sullivan, Inc.

Artificial Intelligence for drug discovery and development has entered a growth phase. This presentation will focus on the commercial aspects and call out major current and emerging application areas of AI/ML within the sector. AI-enabled competencies across big tech and start-ups will be covered followed by a brief assessment of the therapeutic area-wise activity and recent trends. Preview of the emerging ecosystem, partnerships, and selective case studies will be discussed.

10:45 **AI for Mental Health and Wellbeing: Current Status, Trends, and Way Forward**
Kashyap Kompella, CEO and Chief Analyst, RPA2AI Research

Underinvestment in mental healthcare is pervasive across the world. The pandemic further increased the gap between mental health treatments and their availability. AI holds the promise to improve access to mental healthcare but the majority of today's mental health apps are not backed by strong evidence of clinical effectiveness. The way forward is via clinical standards, regulatory oversight, data privacy and protection, transparency of AI and evidence of effectiveness.

11:15 **Sponsored Presentation** *(Opportunity Available)*

11:45 **Closing Remarks**

MEDIA PARTNER **CIOINSIGHTS**
Insights From Technology Leaders

WHY ATTEND?

DISSECT
the Hype of AI & Translate for Your Needs

HEAR
AI Use Cases & Real-World Evidence from Your Peers

GAIN
Tools to Become a Data-Driven & Patient-Centric Organization

TRANSITION
AI from Ideation to Project to Scale for True Value

IMPROVE
Efficiencies & Commercialize AI

SECURE
Talent & Optimal Organizational Structures & Mindsets

SPONSORSHIP OPPORTUNITIES

Whether you're targeting the entire conference community of AI professionals, a topic-specific community, a specific individual, or high-level decision makers, we offer a variety of methods to access our esteemed delegates. Explore our sponsor packages which offer a wide range of platforms to launch products, gain exposure, collect feedback, network and generate new leads.

For more information, please contact

Phillip Zakim-Yacouby
Senior, Business Development Manager
781.247.1815
philzy@
cambridgeinnovationinstitute.com